Moderna and Merck's personalized mRNA cancer vaccine cut melanoma recurrence risk by 42% Oct 26, 2026 · Cris Tolomia The therapy, given with Keytruda, cut the risk of distant metastasis or death by 38%, and overall survival data remain immature Read more »